Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial

The Lancet Rheumatology 2026

View at publisher
Authors: Eric F Morand, Victoria P Werth, Joerg Wenzel, Richard Furie, Maria Dall’Era, J Sanchez-Guerrero, Sanjeev Roy, Summer Goodson, Flavie Moreau, Hans Gühring, Evridiki Sgouroudi, Lena Klopp-Schulze
+1 more David R. Pearson
DOI: 10.1016/s2665-9913(25)00337-6
Cited by: 5
References: 31

Fields of Study & Subjects

Systemic Lupus Erythematosus Research T-cell and B-cell Immunology Liver Diseases and Immunity

Publication details

Journal / source
The Lancet Rheumatology
Publisher
Elsevier BV
Volume
8
Issue
7
Pages
e513–e527
Publication date
7 May 2026
Language
EN